In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cyclacel brings in $14.1mm so far through private placement

Executive Summary

Cyclacel Pharmaceuticals Inc. (main focus is on cancer therapies) netted $14.1mm through the sale of 8.3mm common shares at $1.83 each (an 8% premium) to institutional investors including the Special Situations Funds. Buyers also received five-year warrants to purchase 4.16mm shares at $1.92, and have the option to acquire another $6.9mm of shares and warrants within the next nine months. Lazard Capital Markets and Roth Capital Partners were the placement agents.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies